Multiple Myeloma Clinical Trials
For more information about a clinical trial,
clinical trial eligibility, or informed consent,
contact our research nurses by phone or email:
Please Note: The eligibility criteria noted below are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any treatment to be undertaken must ultimately be determined on an individual basis by the patient and those involved in the patient's treatment. |
Multiple Myeloma Clinical Trials
| Study Title | ||||
|---|---|---|---|---|
| Body Location | Study # | Primary Investigator | More Info | |
Functional Performance of Older Adults with Cancer | ||||
| Breast-Female, Colon, Esophagus, Hodgkins Lymphoma, Kidney, Leukemia, Other, Leukemia, not otherwise specified, Liver, Lung, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Prostate, Rectum, Small Intestine, Stomach, Urinary Bladder | D0836 | Lyons | More Info | |
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation | ||||
| Hodgkins Lymphoma, Leukemia, Other, Leukemia, not otherwise specified, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Hematopoietic | D0748 | Zuckerman | More Info | |
Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma | ||||
| Multiple Myeloma | D0717 | Meehan | More Info | |
Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VTD) versus VELCADE, Melphalan, and Prednisone (VMP) | ||||
| Multiple Myeloma | F0802 | Balan | More Info | |
